赛升药业(300485.SZ)：第三季度净利润同比下降41.41%

Core Viewpoint - Sai Sheng Pharmaceutical (300485.SZ) reported a year-on-year increase in operating revenue for Q3 2025, but a significant decline in net profit attributable to shareholders [1] Financial Performance - Operating revenue for Q3 2025 reached 112 million yuan, representing a year-on-year increase of 3.50% [1] - Net profit attributable to shareholders was 4.0733 million yuan, showing a year-on-year decrease of 41.41% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -12.8664 million yuan [1]